中文摘要：

背景与目的：BCL-6、CD10均为淋巴结生发中心B淋巴细胞（GC—B细胞）的标志，它们在结内外弥漫性大B细胞淋巴瘤（DLBCL）及其它类型淋巴瘤中的表达特征及意义值得研究。本研究分析了B细胞性非霍奇金淋巴瘤（B—NHL）中BCL-6、CD10和BCL-2的蛋白表达及其临床病理意义。方法：免疫组化EnVision两步法分析135例B—NHL常见类型[包括DLBCL 22例，滤泡性淋巴瘤（FL）18例，B小淋巴细胞性淋巴瘤（B—SLL）18例，套细胞淋巴瘤（MCL）15例，淋巴浆细胞性淋巴瘤（LPL）7例，Burkitt’s淋巴瘤（BL）5例，B淋巴母细胞性淋巴瘤（LBL）3例；结外DLBCL 29例，胃粘膜相关淋巴样组织结外边缘区B细胞淋巴瘤（MALT-L）18例]和对照组5例T—NHL、5例结节型淋巴细胞为主型霍奇金淋巴瘤（NLPHL）以及10例淋巴结反应性增生（RLH）石蜡包埋组织中BCL-6、CD10以及BCL-2蛋白的表达。结果：①BCL-6和CD10阳性表达均只见于RLH（100％和100％）、结内DLBCL（72．7％和40．9％）、结外DLBCL（75．9％和41.4％）、FL（88．9％和72．2％）以及BL（100％和100％），其余B—NHL如B-SLL、MCL、MALT—L、LPL、LBL以及T-NHL和NLPHL中均未见BCL-6和CD10蛋白的表达。BCL-2蛋白表达可见于结内、结外DLBCL、FL、B—SLL、MCL、MALT—L以及LBL，阳性率分别为：36．4％、27．6％、83．3％、88．9％、86．7％、72．7％和33．3％；而LPL、BL、T—NHL以及NLPHL未见BCL-2蛋白表达；②DLBCL中BCL-6的表达形式可以分为四种类型：GC／FL型、中间型、散在型和阴性型；③40．9％的结内DLBCL、41．4％的结外DLBCL、72．2％的FL以及100％的BL为BCL-6＋／CD10＋表达，其中BCL-6蛋白表达均为GC／FL型；④在临床特征上，BCL-6＋／CD10＋的结内DLBCL与非BCL-6＋／CD10＋的结内DLBCL相比，前者的临床分期低于后者（P〈0．05）。结论：BCL-6、CD10和BCL-2蛋白的联合检测，可以用于部分B?

英文摘要：

Background and Purpose： Both Bcl-6 and CD10 are markers of germinal center（GC） B cells in the lymph node. Their experssion in nodal diffuse large B cell lympoma（ DLBCL）, extranodal DLBCL and other types of lymphoma and the sigifcance is worthy to he investigated. This paper will investigate the protein expression of BCL-6, CD10, BCL- 2 gene in B-cell Non-Hodgkin＇ s [ymphomas（B-NHL） in Chinese populations and its clinic-pathological significance, Methods： Immunohistochemical analyses of BCL-6, CD10 and BCL-2 protein expression were performed on 135 cases of B- NHL including the common types occurring in Chinese populations and 5 eases of T-NHL, 5 cases of nodular lymphocyte predominance Hodgkin＇ s lymphoma （NLPHL） and 10 eases of Reactive lymphoid hyperplasia （RLH） with paraffin-embedded tissues. Results： ① BCL-6 and CD10 protein were expressed almost exclusively in RLH, nodal DLBCL, extranodal DLBCL, follicular lymphoma （FL） and Burkitt＇ s lymphoma （BL）, the rates of positivity were 100% and 100%, 72.7% and 40.9%, 75.9% and 41.4%, 88.9% and 72.2% as well as 100% and 100%, respectively. BCL-6 and CD10 protein were not expressed in other B-NHL such as small lymphocytic lymphoma （ B-SLL）, mantle cell lymphoma （MCL）, extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue （MALT-L）, Lymphoplasmacytic lymphoma （LPL） and lymphoblastic lymphoma （LBL） as well as T-NHL and NLPHL. BCL-2 protein were expressed in nodal DLBCL,extranodal DLBCL,FL, B-SLL, MCL, MALT-L and LBL, the rates of positivity were 36.4%, 27.6%, 83.3%,88.9% ,86.7% ,72.7% and 33.3%, respectively. BCL-2 protein were not expressed in LPL, BL, T-NHL and NLPHL. ② BCL-6 protein expression in DLBCL could be classified into four patterns. GC/FL pattern, intermediate pattern, sporadic pattern and rare or absent pattern. ③ The coexpression of BCL-6 and CD10 was observed in 40.9% nodal DLBCL, 41. 4% extranodal DLBCL, 72.2% FL and 100% BL. Among them the BCL-6 protein expressions